Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2020 Earnings Presentation
16 slides from Alkem Laboratories's earnings presentation, Aug 12, 2019
Slide 1: Cover letter to stock exchanges
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 12th August, 2019 The Corpo
Slide 2: Alkem reports Q1FY20 Results (press release)
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Press Release Alkem reports
Slide 3: Press release: operational highlights
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Company also built upon its
Slide 4: Q1FY20 Conference Call
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q1FY20 Conference Call at 1
Slide 5: Alkem Laboratories Ltd. Q1FY20
<a> ALKEM Alkem Laboratories Ltd. Investor Presentation Q1FY20 – August 12, 2019
Slide 6: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 7: Key Highlights of Q1FY20
Key Highlights of Q1FY20 • Revenue from Operations grew by 11.5% YoY during the quarter, accompanied by 200 bps YoY improvement in EBITDA margin • Profit After Tax grew by 36.2% compared to the previous year • India Business: As per secondary sales data by IQVIA, for the twelve months ending June 20
Slide 8: Key Financial Highlights – Q1FY20 (Consolidated)
Key Financial Highlights – Q1FY20 (Consolidated) All figures in Rs mn Revenue from Operations India sales 12,222 18,495 10,906 16,589 Q1FY19 Q1FY20 International sales 5,912 5,479 Q1FY19 Q1FY20 Q1FY19 Q1FY20
Slide 9: Key Financial Highlights – Q1FY20 (Consolidated)
Key Financial Highlights – Q1FY20 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 11,377 10,286 2,645 2,037 62.0% 61.5% 12.3% 14.3% Q1FY19 Q1FY20 Q1FY19 Q1FY20 PBT (before Minority Interest) PAT (after Minority Interest) 1,855 2,100 1,362 1,718 Q1FY19 Q1FY2
Slide 10: India Business
India Business India Business: Q1FY20 Sales of Rs.12,222 million (12.1% YoY growth) • India sales contributed 67.4% to total sales in Q1FY20 • As per secondary sales data by IQVIA, for the twelve months ended June 2019, Alkem gained one rank and now features amongst the top five pharmaceutical compa
Slide 11: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across most of the major therapeutic areas in Q1FY20 Established therapeutic areas of Alkem Market rank 1 3 3 4 22.0% 23.5% 17.5% 13.8% 12.0% 12.0% 10.5% 8.8% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients
Slide 12: US Business
US Business US Business: Q1FY20 Sales of Rs.4,817 million (13.7% growth YoY) • US sales contributed 26.6% to total sales in Q1FY20 • In Q1FY20, the Company filed 2 ANDAs with the US FDA and received 5 approvals (including 2 tentative approval) • As on June 30, 2019, the Company has filed a total of
Slide 13: Update on the US FDA inspection
Update on the US FDA inspection Facility Scope Last inspection Status post last inspection Baddi (India) Formulation May 2019 EIR# received in July 2019, thereby successfully closing the inspection St. Louis (US) Formulation February – March 2019 Received Form 483 with 8 observations. Plant classifi
Slide 14: Other International Business
Other International Business Other International Business: Q1FY20 Sales of Rs.1,095 million (decline of 11.8% YoY) • Other International Market sales contributed 6.0% to total sales in Q1FY20 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Chile and
Slide 15: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on June 30, 2019 Non-Institution, 25.28% Promoter & Institution, Promoter Group, 8.69% 66.03% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodies
Slide 16: Thank You
Thank You